Dashti, Hassan S. http://orcid.org/0000-0002-1650-679X
Jones, Samuel E. http://orcid.org/0000-0003-0153-922X
Wood, Andrew R.
Lane, Jacqueline M.
van Hees, Vincent T. http://orcid.org/0000-0003-0182-9008
Wang, Heming http://orcid.org/0000-0002-1486-7495
Rhodes, Jessica A.
Song, Yanwei http://orcid.org/0000-0002-2411-6548
Patel, Krunal
Anderson, Simon G. http://orcid.org/0000-0002-8896-073X
Beaumont, Robin N.
Bechtold, David A. http://orcid.org/0000-0001-8676-8704
Bowden, Jack
Cade, Brian E.
Garaulet, Marta
Kyle, Simon D.
Little, Max A. http://orcid.org/0000-0002-1507-3822
Loudon, Andrew S.
Luik, Annemarie I.
Scheer, Frank A. J. L. http://orcid.org/0000-0002-2014-7582
Spiegelhalder, Kai
Tyrrell, Jessica http://orcid.org/0000-0002-9256-6065
Gottlieb, Daniel J.
Tiemeier, Henning
Ray, David W. http://orcid.org/0000-0002-4739-6773
Purcell, Shaun M.
Frayling, Timothy M.
Redline, Susan
Lawlor, Deborah A. http://orcid.org/0000-0002-6793-2262
Rutter, Martin K.
Weedon, Michael N.
Saxena, Richa http://orcid.org/0000-0003-2233-1065
Article History
Received: 1 November 2018
Accepted: 31 January 2019
First Online: 7 March 2019
Competing interests
: F.A.J.L.S. has received speaker fees from Bayer Healthcare, Sentara Healthcare, Philips, Kellogg Company, and Vanda Pharmaceuticals. M.K.R. reports receiving research funding from Novo Nordisk, consultancy fees from Novo Nordisk and Roche Diabetes Care, and modest owning of shares in GlaxoSmithKline. The remaining authors declare no competing interests.